New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
09:16 EDTSGMOSangamo price target raised to $27 from $22 at JMP Securities
JMP Securities increased its price target on Sangamo after meeting with the company's clinical and scientific team. The firm increased its estimate of the likelihood of the company's HIV program succeeding to 60% from 50%. JMP Securities thinks the company is clicking on all cylinders, and reiterates an Outperform rating on the shares.
News For SGMO From The Last 14 Days
Check below for free stories on SGMO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 23, 2014
10:02 EDTSGMOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:03 EDTSGMOSangamo initiated with a Buy at Jefferies
Subscribe for More Information
September 15, 2014
07:27 EDTSGMOIBC Life Sciences to hold a conference
Subscribe for More Information
September 10, 2014
07:06 EDTSGMOSangamo plans to submit IND application for hemophilia B in 2Q15
Sangamo BioSciences (SGMO) plans to submit an Investigational New Drug application for the treatment of hemophilia B in Q2 2015. This program, partnered with Shire (SHPG), is the first therapeutic application of Sangamo's zinc finger nuclease-mediated In Vivo Protein Replacement Platform. Sangamo is developing the IVPRP as a generally applicable strategy to provide a one-time, permanent genetic cure for monogenic diseases that are currently managed by protein replacement therapy, which involves costly repeat infusions over the lifetime of the patient.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use